

Special Issue

The Role of Adenovirus in Cancer Therapy

Message from the Guest Editor

Dear colleagues, Adenovirus has been employed for cancer gene therapy for years by taking advantage of its high in vivo transduction efficiency. While the early applications using replication-deficient adenovirus vectors to express transgenes did not meet the initial expectations, the exploitation of the latest technologies and their combination with other therapies has achieved a much better effect in vivo as well as in human clinical trials. Most of the novel approaches are the result of the effort to overcome the obstacles of the adenovirus vector system. In this Special Issue, we aim to review recent advances in adenovirus vector technologies, such as oncolytic adenovirus as well as combination with other therapies toward clinical application.

Guest Editor

Prof. Dr. Masato Yamamoto

1. Division of Basic and Translational Research, Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
2. Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA

Deadline for manuscript submissions

closed (31 March 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/27369

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)